Mezigdomide, Carfilzomib, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma in Patients With Extramedullary Disease

Official title

Phase II Clinical Trial of Mezigdomide/Carfilzomib/Dexamethasone (MeziKD) in Patients With Relapsed or Refractory Multiple Myeloma (MM) With Extramedullary Disease (EMD)

Overview

This phase II trial studies how well mezigdomide/carfilzomib/dexamethasone (MeziKD) works in treating patients with multiple myeloma (MM) that has come back after a period of improvement (relapsed) or that does not respond to treatment (refractory) and have tumors from myeloma cells outside the bone marrow in the soft tissues or organs of the body (extramedullary disease \[EMD\]). Mezigdomide blocks important processes in myeloma cells and may lead to modulation of the immune system, including activation of T-lymphocytes, and downregulation of the activity of other proteins, some of which play key roles in the proliferation of certain cancer cell types. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dexamethasone is a type of corticosteroid and is used to kill myeloma cells. It is used with other drugs to treat multiple myeloma. Giving MeziKD may kill more cancer cells in patients with relapsed/refractory multiple myeloma (RRMM) with EMD.

Interventions

• Biological Mezigdomide
  Given PO
• Drug Carfilzomib
  Given IV
• Drug Dexamethasone
  Given PO
• Procedure Echocardiography
  Undergo ECHO
• Procedure Positron Emission Tomography
  Undergo PET/CT
• Procedure Computed Tomography
  Undergo PET/CT
• Procedure Computed Tomography Assisted Biopsy
  Undergo CT guided tumor Biopsy
• Procedure Bone Marrow Aspiration
  Undergo bone marrow aspiration biopsy
• Procedure Bone Marrow Biopsy
  Undergo bone marrow biopsy
• Procedure Biospecimen Collection
  Undergo blood and saliva sample collection

Primary outcome measures

• Overall Response Rate [Time frame: At the end of cycle 6 (each cycle is 28 days).]
• Clinical benefit rate [Time frame: At the end of cycle 6 (each cycle is 28 days)]

Secondary outcome measures (5)

• Incidence of Adverse Events (AEs) [Time frame: Up to 30 days after last dose of study drug]
• Duration of response [Time frame: From the first documentation of response (≥ PR) to the first documentation of progressive disease or death, assessed up to 3 years]
• Progression Free survival [Time frame: Time from first dose of mezigdomide to disease progression or death from any cause, whichever occurs first, assessed up to 3 years]
• Overall Survival [Time frame: Time from first dose of mezigdomide to death from any cause, assessed up to 3 years]
• Imaging Response [Time frame: At screening, after 3 cycles of treatment (or progression, whichever occurs first), after 6 cycles of treatment, and then every 6 months for 3 years or until progression, start of a new therapy, or death (whichever occurs first)]

Eligibility criteria

Inclusion criteria

• Age ≥ 18 years of age
• Have an Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2
• RRMM patients with one or more prior lines of therapy with at least one ES or PS lesion that is accessible to a biopsy. Accessibility will be assessed by the MM tumor board
• Measurable disease meeting at least one of the following:

• Serum M-protein ≥1 g/dL
• Urine M-protein ≥200 mg/24 h
• Serum FLC assay: involved FLC level ≥10 mg/dL provided serum FLC ratio is abnormal
• Up to 10 patients without measurable disease can be enrolled but screening imaging and/or bone marrow biopsy have to confirm RRMM. Follow-up response assessment will be performed with imaging using RECIST 1.1 and Deauville Criteria and bone marrow biopsies
• Absolute neutrophil count: ≥ 1 x 10\^9/L
• Platelets: ≥ 75 x 10\^9/L
• Total bilirubin: ≤ 1.5 x upper limit of normal (ULN)
• Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \[SGPT\]): ≤ 3 x ULN
• Renal function: Estimated creatinine clearance ≥ 30 mL/min (Cockroft-Gault)
• Adequate cardiac pump function with a left ventricular ejection fraction of ≥ 40%
• Women of child-bearing potential must agree to use adequate contraceptive methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for at least 28 days after the last dose of mezigdomide or 6 months after the last dose of carfilzomib. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
• Male patients (non-vasectomized) must agree to use contraception during the treatment period and for at least 28 days after the last dose of mezigdomide or 3 months after the last dose of carfilzomib and refrain from donating sperm during this period
• Participant must understand the investigational nature of this study and sign an independent ethics committee/institutional review board approved written informed consent form prior to receiving any study related procedure

Exclusion criteria

• Participant has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, pomalidomide (including ≥ grade 3 rash during prior thalidomide, lenalidomide, or pomalidomide therapy), carfilzomib or dexamethasone, any cereblon E3 ligase modulators (CELMoD) agents, or the excipients contained in the formulations, or participant has any contraindications per local prescribing information
• Administration of strong CYP3A modulators or proton-pump inhibitors (e.g., omeprazole, esomeprazole, lansoprazole, pantoprazole, rabeprazole) within 2 weeks of starting study intervention
• Participant is unable or unwilling to undergo protocol required thromboembolism prophylaxis
• Patient has evidence of mucosal or internal bleeding and/or is platelet transfusion refractory
• Any medical conditions that, in the investigator's opinion, would impose excessive risk to the patient or would adversely affect his/her participation in this study
• Known active infection requiring parenteral or oral anti-infective treatment within the past 14 days
• Participant has a history of prior malignancy other than MM, except if the participant has been free of disease for ≥ 3 years or the participant had 1 of the following noninvasive malignancies treated with curative intent without known recurrence:

• Basal or squamous cell carcinoma of the skin
• Carcinoma in situ of the cervix or breast
• Stage 1 bladder cancer
• Incidental histological findings of localized prostate cancer such as tumor stage 1a or 1b (T1a or T1b) using the tumor, nodes, and metastasis (TNM) classification of malignant tumors OR prostate cancer that has been treated with curative intent
• Other ongoing anti-myeloma therapy. Patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids for symptom management and comorbid conditions. Doses of corticosteroid should be stable for at least 7 days prior to patient registration
• Pregnant or breast-feeding females
• Serious psychiatric illness, active alcoholism, or drug addiction that may hinder or confuse follow-up evaluation
• Known active HIV or hepatitis B or C viral infection
• Known history of HIV infection
• Systemic amyloidosis or POEMS syndrome (plasma cell dyscrasia with polyneuropathy, organomegaly, endocrinopathy, monoclonal protein \[M-protein\] and skin changes)
• Prior peripheral stem cell transplant within 12 weeks of study enrollment
• Radiotherapy within 14 days prior to cycle 1 day 1. However, if the radiation portal covered ≤ 5% of the bone marrow reserve, the patient may be enrolled irrespective of the end date of radiotherapy
• Known intolerance to steroid therapy
• Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, severe cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Carfilzomib-refractory in the most recent line of therapy
• Prior treatment with mezigdomide
• Contraindication against conscious sedation
• Unwilling or unable to follow protocol requirements
• Any condition which in the investigator's opinion deems the participant an unsuitable candidate to receive study drug

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

United States · 1 center

• Roswell Park Cancer Institute — Buffalo

Identifiers

NCT: NCT06627751 · I-3576824

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗